6/7/2023

Question 1

Lotensin

Answer 1

Benazepril

Question 2

Benazepril MOA

Answer 2

Prevents angiotensin I from being converted to angiotensin II by competitive inhibition, therefore preventing vasoconstriction.

Question 3

Benazepril class

Answer 3

ACE inhibitor

Question 4

Cogentin

Answer 4

Benztropine

Question 5

Benztropine MOA

Answer 5

Anticholinergic and antihistaminic effects

Question 6

Benztropine class

Answer 6

Anti-Parkinson agent, anticholinergic

Question 7

Avastin

Answer 7

Bevacizumab

Question 8

Bevacizumab MOA

Answer 8

Inhibits VEGF signaling pathways, therefore preventing vascular proliferation

Question 9

Bevacizumab class

Answer 9

Antineoplastic, VEGF inhibitor

Question 10

Lumigan

Answer 10

Bimatoprost

Question 11

Bimatoprost MOA

Answer 11

Synthetic analog of prostaglandin; decreases intraocular pressure by increasing outflow of aqueous humor.

Question 12

Bimatoprost class

Answer 12

Prostaglandin

Question 13

Velcade

Answer 13

Bortezomib

Question 14

Bortezomib MOA

Answer 14

Reversibly inhibits chymotrypsin-like activity at the 26S proteasome, leading to activation of signaling cascades, cell cycle arrest, and apoptosis.

Question 15

Bortezomib class

Answer 15

Antineoplastic, proteasome inhibitor

Question 16

Lumify

Answer 16

Brimonidine

Question 17

Brimonidine MOA

Answer 17

Alpha-2 adrenergic agonist; causes reduction of aqueous humor formation and increased uveoscleral outflow

Question 18

Brimonidine class

Answer 18

Alpha-2 adrenergic agonist

Question 19

Suboxone

Answer 19

Buprenorphine/Naloxone

Question 20

Buprenorphine/Naloxone MOA

Answer 20

Buprenorphine - exerts analgesic effect via high affinity binding receptors in the CNS; partial mu agonist and weak kappa antagonist

Naloxone - opioid antagonist that competes with and displaces opioids at opioid receptor sites

Question 21

Buprenorphine/Naloxone class

Answer 21

Opioid analgesic/opioid partial agonist

Question 22

Zyban

Answer 22

Bupropion

Question 23

Wellbutrin

Answer 23

Bupropion

Question 24

Bupropion MOA

Answer 24

Inhibits neuronal uptake of norepinephrine and dopamine

Question 25

Bupropion class

Answer 25

Dopamine/norepinephrine reuptake inhibitor, antidepressant

Question 26

Buspirone MOA

Answer 26

high affinity for serotonin receptors; moderate affinity for dopamine D2 receptors

Question 27

Buspirone class

Answer 27

Miscellaneous antianxiety agent

Question 28

Jevtana

Answer 28

Cabazitaxel

Question 29

Cabazitaxel MOA

Answer 29

Microtubule inhibitor; binds to tubulin, promoting assembly into microtubules and inhibiting their disassembly and stopping the cell cycle

Question 30

Cabazitaxel class

Answer 30

Antimicrotubular antineoplastic agent; taxane derivative

Question 31

Caffeine MOA

Answer 31

Increases levels of 3’5’ cAMP by inhibiting phosphodiesterase. CNS stimulant, which increases medullary respiratory center sensitivity to carbon dioxide, stimulates central inspiratory drive, and improves skeletal muscle contraction

Question 32

Caffeine class

Answer 32

CNS stimulant; phosphodiesterase inhibitor

Question 33

Cannabidiol MOA

Answer 33

unknonwn

Question 34

Cannabidiol class

Answer 34

Cannabinoid; antiseizure agent

Question 35

Capsaicin MOA

Answer 35

Agonist for transient receptor potential vanilloid 1 receptor (TRPV1), an ion channel receptor complex expressed on nociceptive nerve fibers in the skin. Causes initial stimulation of TRPV1-expressing cutaneous nociceptors that may cause painful sensations, followed by pain relief caused by downregulation of TRPV1-expressing nociceptive nerve endings.

Question 36

Capsaicin class

Answer 36

Topical analgesic; TRPV1 agonist

Question 37

Tegretol

Answer 37

Carbamazepine

Question 38

Carbamazepine MOA

Answer 38

Decreases temporal stimulation leading to neural discharge by limiting influx of sodium ions across the cell membrane

Question 39

Carbamazepine class

Answer 39

Antizeisure agent

Question 40

Sinemet

Answer 40

Carbidopa/levodopa

Question 41

Carbidopa/levodopa MOA

Question 42

Carbidopa/levodopa class

Answer 42

Anti-parkinson agent

Question 43

Rytary

Answer 43

Carbidopa/levodopa

Question 44

Duopa

Answer 44

Carbidopa/levodopa

Question 45

Carbidopa/levodopa MOA

Answer 45

Levodopa crosses the BBB where it is converted to dopamine

Carbidopa inhibits peripheral breakdown of levodopa by inhibiting its decarboxylation, thereby increasing available levodopa at the BBB